Vous êtes sur la page 1sur 9

Soft Tissue Sarcoma - Pipeline Review, H2 2015 Now

Available at iData Insights


Soft Tissue Sarcoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Soft Tissue Sarcoma Pipeline Review, H2 2015, provides an overview of the Soft Tissue Sarcomas therapeutic pipeline. This
report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma,
complete with comparative analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players involved in the therapeutic
development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser
based alert-box and clinical trials registries tracking ensure that the most recent developments are
captured on a real time basis. The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying
new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the
report may be removed or altered based on the availability and relevance of data for the indicated
disease. Scope - The report provides a snapshot of the global therapeutic landscape of Soft Tissue
Sarcoma - The report reviews key pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and
enlists all their major and minor projects - The report summarizes all the dormant and discontinued
pipeline projects - A review of the Soft Tissue Sarcoma products under development by companies and
universities/research institutes based on information derived from company and industry-specific
sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and
combination therapy pipeline projects - Coverage of the Soft Tissue Sarcoma pipeline on the basis of
target, MoA, route of administration and molecule type - Latest news and deals relating related to
pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies - Identify emerging players with
potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Soft Tissue
Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising
pipeline - Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma
pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173360/soft-tissuesarcoma-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173360/soft-tissue-sarcoma-pipeline-review-h2-2015


Table of Contents

Introduction 9
Global Markets Direct Report Coverage 9
Soft Tissue Sarcoma Overview 10
Therapeutics Development 11
Pipeline Products for Soft Tissue Sarcoma - Overview 11
Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis 12
Soft Tissue Sarcoma - Therapeutics under Development by Companies 13
Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes 18
Soft Tissue Sarcoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Soft Tissue Sarcoma - Products under Development by Companies 23
Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes 29
Soft Tissue Sarcoma - Companies Involved in Therapeutics Development 30
A. Menarini Industrie Farmaceutiche Riunite Srl 30
Advanced Proteome Therapeutics Corporation 31
Advenchen Laboratories, LLC 32
Altor BioScience Corporation 33
Amgen Inc. 34
2

Arog Pharmaceuticals, Inc. 35


Bayer AG 36
Bellicum Pharmaceuticals, Inc. 37
Boehringer Ingelheim GmbH 38
CASI Pharmaceuticals Inc. 39
Celgene Corporation 40
Cell Medica Limited 41
Cellceutix Corporation 42
Cellectar Biosciences, Inc. 43
CytRx Corporation 44
Daiichi Sankyo Company, Limited 45
Double Bond Pharmaceutical International AB 46
Eisai Co., Ltd. 47
Eli Lilly and Company 48
EpiZyme, Inc. 49
Exelixis, Inc. 50
F. Hoffmann-La Roche Ltd. 51
Gem Pharmaceuticals, LLC 52
GlaxoSmithKline Plc 53
Immune Design Corp. 54
Karyopharm Therapeutics, Inc. 55
Loxo Oncology, Inc. 56
Lytix Biopharma AS 57
MedImmune, LLC 58
Merck & Co., Inc. 59
Merrimack Pharmaceuticals, Inc. 60

Mirati Therapeutics Inc. 61


MolMed S.p.A. 62
Morphotek, Inc. 63
Northwest Biotherapeutics, Inc. 64
Novartis AG 65
Noxxon Pharma AG 66
OncoTherapy Science, Inc. 67
Onxeo SA 68
Pfizer Inc. 69
Pharma Mar, S.A. 70
Philogen S.p.A. 71
Plexxikon Inc. 72
Polaris Pharmaceuticals, Inc. 73
Recombio S.L 74
Rigontec GmbH 75
Sanofi 76
Shionogi & Co., Ltd. 77
Siena Biotech S.p.A. 78
Sigma-Tau S.p.A. 79
Sumitomo Dainippon Pharma Co., Ltd. 80
Targovax AS 81
Threshold Pharmaceuticals, Inc. 82
TRACON Pharmaceuticals, Inc. 83
Vicore Pharma AB 84
Soft Tissue Sarcoma - Therapeutics Assessment 85
Assessment by Monotherapy Products 85
Assessment by Combination Products 86
4

Assessment by Target 87
Assessment by Mechanism of Action 94
Assessment by Route of Administration 99
Assessment by Molecule Type 101
Drug Profiles 103
afatinib dimaleate - Drug Profile 103
AL-3818 - Drug Profile 108
aldoxorubicin hydrochloride - Drug Profile 110
ALT-836 - Drug Profile 113
APC-103 - Drug Profile 115
belinostat - Drug Profile 116
BI-853520 - Drug Profile 119
C-21 - Drug Profile 120
cabazitaxel - Drug Profile 122
cabozantinib s-malate - Drug Profile 124
cancer vaccine - Drug Profile 128
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 129
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 130
celyvir - Drug Profile 132
CMD-003 - Drug Profile 134
crenolanib besylate - Drug Profile 136
DCVax-Direct - Drug Profile 138
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 139
Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile 140
DSR-6434 - Drug Profile 141
durvalumab + tremelimumab - Drug Profile 142

efatutazone - Drug Profile 144


emactuzumab - Drug Profile 146
ENMD-2076 - Drug Profile 147
eribulin mesylate - Drug Profile 149
everolimus - Drug Profile 155
evofosfamide - Drug Profile 161
Fibromun - Drug Profile 169
G-100 - Drug Profile 171
GPX-150 - Drug Profile 173
GSK-3174998 - Drug Profile 176
HDM-201 - Drug Profile 177
I131-CLR1404 - Drug Profile 178
ID-LV305 + ID-G305 - Drug Profile 180
ImOl-100 - Drug Profile 182
irinotecan hydrochloride - Drug Profile 183
KM-3174 - Drug Profile 186
KRA-0008 - Drug Profile 190
LK-3 - Drug Profile 191
LOXO-101 - Drug Profile 192
LTX-315 - Drug Profile 194
LV-305 - Drug Profile 196
MAT-303 - Drug Profile 197
mocetinostat - Drug Profile 198
MVXONCO-1 - Drug Profile 201
NGR-hTNF - Drug Profile 202
NOV-110501 - Drug Profile 206
NOXS-93 - Drug Profile 207
6

olaratumab - Drug Profile 208


ONCOS-102 - Drug Profile 211
ontuxizumab - Drug Profile 213
OTSA-101 - Drug Profile 215
paclitaxel albumin bound - Drug Profile 216
palbociclib - Drug Profile 220
panobinostat - Drug Profile 224
pazopanib hydrochloride - Drug Profile 230
pembrolizumab - Drug Profile 236
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 245
PF-03084014 - Drug Profile 247
PLX-7486 - Drug Profile 249
regorafenib - Drug Profile 250
ribociclib - Drug Profile 254
roneparstat - Drug Profile 257
S-588410 - Drug Profile 258
SA-083 - Drug Profile 259
sabarubicin - Drug Profile 260
selinexor - Drug Profile 262
SEN-461 - Drug Profile 268
talimogene laherparepvec - Drug Profile 269
tazemetostat - Drug Profile 272
TNF-PEG 20 - Drug Profile 274
trabectedin - Drug Profile 275
TRC-105 - Drug Profile 280
Vaccine for Soft Tissue Sarcoma - Drug Profile 283

vorinostat - Drug Profile 284


Soft Tissue Sarcoma - Recent Pipeline Updates 288
Soft Tissue Sarcoma - Dormant Projects 449
Soft Tissue Sarcoma - Discontinued Products 453
Soft Tissue Sarcoma - Product Development Milestones 454
Featured News & Press Releases 454
Appendix 463
Methodology 463
Coverage 463
Secondary Research 463
Primary Research 463
Expert Panel Validation 463
Contact Us 463
Disclaimer 464

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173360/soft-tissuesarcoma-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects